Description

Lexanib® is a prescription anticancer medicinal product containing lenvatinib, a targeted therapy agent belonging to the class of multi-target tyrosine kinase inhibitors (TKIs). It is used in oncology for the treatment of certain malignant tumors and must be administered only under the supervision of a qualified healthcare professional.

---

🔹 Pharmacological group

Antineoplastic agents
Protein kinase inhibitors
Tyrosine kinase inhibitors
ATC code: L01EX08

---

🔹 Active substance

Lenvatinib — 10 mg per capsule

---

🔹 Mechanism of action

Lenvatinib inhibits multiple receptor tyrosine kinases involved in tumor proliferation and angiogenesis, including vascular endothelial growth factor receptors (VEGFR). By blocking these pathways, the drug:

• suppresses tumor cell growth

• inhibits formation of new blood vessels supplying tumors

• reduces tumor progression

• may slow metastatic spread

This targeted mechanism allows selective interference with tumor signaling pathways.

---

🔹 Indications

Prescribed as part of oncological therapy for certain malignancies, including:

• differentiated thyroid carcinoma refractory to radioactive iodine

• hepatocellular carcinoma (in selected treatment protocols)

• renal cell carcinoma (usually in combination therapy)

Specific indication, dosing, and regimen are determined individually by an oncologist according to clinical guidelines.

---

🔹 Administration

• taken orally

• capsules should be swallowed whole with water

• may be taken with or without food

• dosage is individualized based on diagnosis, patient condition, tolerability, and organ function

Dose adjustment or discontinuation must only be performed by a physician.

---

🔹 Contraindications

Not recommended in case of:

• hypersensitivity to components

• pregnancy or breastfeeding

• severe hepatic impairment

• serious cardiovascular disorders (as assessed by physician)

---

🔹 Special warnings and precautions

Regular medical monitoring is required during therapy because lenvatinib may affect:

• blood pressure

• liver function

• renal parameters

• heart rhythm

• hematologic values

Patients should undergo periodic laboratory and clinical evaluations.

---

🔹 Possible adverse reactions

Commonly reported effects may include:

• fatigue and weakness

• hypertension

• decreased appetite

• nausea or diarrhea

• laboratory abnormalities

Severe or persistent symptoms require immediate medical consultation.

---

🔹 Drug interactions

Lenvatinib may interact with other medications, especially those affecting cardiac rhythm, blood pressure, or coagulation. Patients should inform their physician about all medicines, supplements, and herbal products they are taking.

---

🔹 Storage conditions

• store below 25°C

• protect from moisture and light

• keep in original packaging

• keep out of reach of children

🔹 Dosage form

Hard capsules for oral administration.

⚠️ Important: This medicine is supplied by prescription only. Treatment should be conducted strictly under specialist supervision.